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Patients with malignant neoplastic diseases represent a high-risk population relative to thromboembolic disease. With the
advent of improved and accessible diagnostic technology, for example, ultrasound and/or spiral CT scans, timely diagnosis of
venous thromboembolic events (VTE) is readily accomplished. The introduction of low-molecular-weight heparin (LMWH)
approximately two decades ago (in contrast to unfractionated heparin and vitamin K antagonists) has provided a class of agents
with a favorable therapeutic index. In the review to follow, the literature regarding the use of LMWH in oncologic patient
populations is summarized. Topics addressed include prophylaxis, and treatment as well as consideration of the potential anti-
neoplastic properties of this class of drugs.
1.Introduction
Itiswellrecognizedthatcancerpatientsareatriskforvenous
thromboembolicevents(VTEs)[1]withanestimatedannual
incidence of VTE in the cancer population ﬁve times
higher than the general population [2]. This is in part
due to chronic hemostatic activation and changes, including
increased platelet adhesion and disseminated intravascu-
lar coagulation, which are commonly observed in cancer
patients [3–10]. Although it is diﬃcult to compare rates
across studies, several generalizations regarding VTE can
be made. An estimated 15% of all patients with cancer
will develop VTE during their clinical course [11]. The
risk of developing VTE is signiﬁcantly higher even early
in diagnosis with a reported >50-fold higher incidence in
the ﬁrst 3 months following a diagnosis of cancer in one
case controlled study [12]. Patients admitted to an inpatient
oncology service are reported to have rates of VTE up to 8%
[13, 14]; those who have a remote diagnosis of cancer are at a
lower risk, as would be expected [13, 15, 16]. Additionally,
other factors may represent more signiﬁcant risk variables
in cancer patients such as certain types of chemotherapy
[17, 18].
Chemotherapy is associated with a 2- to 6-fold increased
risk of VTE referenced to the general population [17–
19]. For instance, in a study of 205 patients with stage
II breast cancer randomized to 36 weeks of chemotherapy
(cyclophosphamide, methotrexate, ﬂuorouracil, vincristine,
and prednisone) or 12 weeks of chemohormonal therapy
(cyclophosphamide, methotrexate, ﬂuorouracil, vincristine,
prednisone, doxorubicin, and tamoxifen), there was a 6.8%
incidence of deep venous thrombosis (DVT). Of note, all
of the events occurred during the chemotherapy treatment
period, suggesting that chemotherapy for breast cancer
contributes to thrombosis [20]. A prospective observational
study by Khorana et al. in 2007 showed VTE as one of
the leading causes of noncancer death among 4,466 patients
receiving outpatient chemotherapy, with 9.2% of deaths
secondary to VTE and one death related to pulmonary
embolism in a patient without known metastatic disease
[19]. This is a trend that was again demonstrated in a
prospective study of 4,000 patients which showed VTE was2 Thrombosis
an independent risk factor for mortality during the ﬁrst
months of chemotherapy even after adjusting for several risk
factors. Cancer diagnosed at the same time or within 1 year
after an episode of VTE was associated with worse prognosis
and relatively low rate of survival at one year (38 percent
versus 47 percent in the control group) [21].
Although speciﬁc incidence rates may vary based on
the clinical setting, recent reviews have highlighted the
signiﬁcance of histological diagnosis [18, 22]. Patients with
cancers of the pancreas [23]a n db r a i n[ 24], in some series,
can have rates exceeding 25%; other cancers associated with
the highest rates of VTE exceeding 5% include cancers of
the gastrointestinal tract, ovary, uterus, kidney, and lung
[18]. More recent studies have identiﬁed VTE in association
with hematologic malignancies as being comparable to solid
tumor patients [22]. It is interesting to note oncogenes
responsible for neoplastic transformation in leukemia also
may be involved in clotting activation [22]. As is the case
with solid tumors, therapy for hematologic malignancies can
place patients at increased risk. For example, thalidomide
[25, 26] and lenalidomide [27, 28] have been associated with
high rates of VTE exceeding 25%. In addition to malignancy
as a risk factor, other interventions in cancer patients, such
as surgery and the use of venous access devices, may further
increase the risk for thromboembolic complications [29].
In summary, as VTE contributes to morbidity and is one
oftheleadingcausesofnoncancerdeathamongpatientswith
cancer [19, 21, 30], the timely diagnosis and eﬀective treat-
ment of VTE is of paramount importance. In the following
text we will discuss the existing data for the treatment and
prophylaxis of VTE in cancer patients. The review will focus
on the use of low-molecular-weight heparins (LMWHs), as
the published literature and experience center on this class
of anticoagulants in relation to both safety and eﬃcacy.
Encompassed in this discussion will be a review of the
data suggesting the potential for antineoplastic eﬀects with
the application of LMWH, and their inﬂuence on patient
outcomes. Relative to this, there are in vitro and animal
studies showing anticoagulants, in particular the LMWHs,
have an antineoplastic eﬀect through mechanisms such as
interference with tumor cell adhesion, invasion, metastasis
formation, and angiogenesis [31–42].
2.Low-Molecular-WeightHeparinasTreatment
for Venous Thromboembolism
2.1. Pharmacology and Pharmacokinetics of Low-Molecular-
Weight Heparin. There are various FDA approved LMWHs
commercially available which are produced by chemical
or enzymatic depolymerization of unfractionated heparin
(UFH). The fragmented LMWHs are approximately 1/3 the
size of UFH and range from 4,000–6,500 Daltons with a
chain length of 12–22 polysaccharides. LMWH’s anticoagu-
lant activity is similar to UFH; however, a shortened polysac-
charide chain allows for more speciﬁc binding to inhibit
factor Xa. Unfractionated heparin binds to antithrombin,
initiating inhibition of several serine proteases in the coag-
ulation cascade, including factor IIa and Factor Xa. The
polysaccharide chain is truncated in LMWHs while retaining
the high aﬃnity pentasaccharide binding sites. This results
in inhibition of factor Xa, but the shortened polysaccharide
chain is relatively ineﬀective at binding, resulting in loss of
inhibition of factor IIa [43]. In terms of anticoagulation, this
results in a reduced antifactor IIa activity relative to factor Xa
and improved pharmacokinetics.
Unfractionated heparin is generally given intravenously
(if used therapeutically) and requires close monitoring of
activated partial thromboplastin time (APTT) with frequent
dose adjustments. In contrast, LMWHs are injected subcu-
taneously once or twice daily and do not typically require
routine monitoring. Special considerations for monitoring
should be given for patients with renal failure and obesity.
LMWHs are cleared by the kidneys, and dosing is weight
based. The biological half-life is prolonged in patients with
renal failure. Dosing in renal failure and weight adjusted
dosing were not addressed in original clinical trials, and
monitoring of anti-Xa levels is recommended [44, 45].
Monitoring in pregnancy may also be considered given the
relative increase in renal clearance [46]. Anti-Xa levels can be
monitored in serum levels 4 hours following subcutaneous
administration. Various labs are available for monitoring
anti-Xa levels, and the target therapeutic range is 0.6–
1.0IU/mL [47, 48].
2.2. Safety and Eﬃcacy. Many consider LMWH as the agent
of choice for the initial and long-term treatment of VTE
in patients with neoplastic disease, based on randomized
clinical studies [19, 49–52]. In 2003, Lee et al. conducted
a randomized study of cancer patients with VTE: 336
patients received dalteparin at 200IU/kg daily for 5 to 7 days
followed by a vitamin K antagonist with target international
normalized (INR) ratio of 2-3 for 6 months, whereas the
other 336 patients received dalteparin at 200IU/kg daily
for 1 month followed by 150IU/kg daily for 5 months
[53]. (It should be noted that the concept of a 25% dose
reduction after initial therapy was an arbitrary choice, and
not evaluated in comparison to other possibilities.) In this
study,thecumulativeriskofsymptomaticandrecurrentVTE
during 6 months of anticoagulation was 17% for patients
treated with a vitamin K antagonist, compared with 9% for
patients treated with dalteparin, a LMWH [53]. The relative
risk reduction of 52% was statistically signiﬁcant (hazard
ratio = 0.48; P = .002). One episode of recurrent VTE
was prevented for every 13 patients treated with dalteparin.
In terms of side eﬀects, no diﬀerence in major or minor
bleeding was detected between the groups, with 6% of
dalteparin-treatedpatientsand4%ofcontrolpatientshaving
major bleeding episodes [53].
In another study with a similar design, Meyer and col-
leagues randomized 138 patients to receive either enoxaparin
at 1.5mg/kg daily for 4 days followed by warfarin with
target INR of 2-3 for 3 months, or enoxaparin at 1.5mg/kg
daily for 3 months [50]. There was a consistent but not
statisticallysigniﬁcantbeneﬁtwithenoxaparinoverwarfarin,
in terms of decreased VTE recurrence or major bleeding
[50]. Of note, the experience with LMWH has shown
good patient adherence with self-injection [49–51, 53].Thrombosis 3
Further, it should be noted in comparison to unfractionated
heparin, LMWH reduces the risk of recurrent thrombosis
by 32%, major bleeding by 43%, and death by 24% [54].
Thus, in considering the aforementioned observations taken
collectively, LMWH can be considered a preferred agent for
treatment of cancer-associated VTE because of its eﬃcacy,
safety, and convenience.
One special case for VTE treatment with LMWH,
which deserves special consideration, relates to patients with
high grade gliomas, for example, glioblastoma multiforme
(GBM). VTE occurs in 20–30% of patients with malignant
glioma per year of survival [55, 56]. These patients are also
at high risk for bleeding with and without anticoagulation.
In one study discussed in detail below (Section 3, Glioma),
the incidence of bleeding was 5.1% [57]. In a review on the
subject, Chao and Robins suggested treating VTE in patients
with GBM with full dose LMWH until resolution of symp-
toms from their thrombosis (usually within 2 weeks of onset
of VTE), followed by 50% dose reduction in the following
month, and followed by another 25% dose reduction after 2
to 3 months [58]. They further recommended dividing the
total daily dose during the acute phase of therapy into twice-
a-day or split dosing to reduce bleeding risk. Parenthetically,
one study demonstrated split dosing of dalteparin was more
eﬃcacious [59]. Two other studies, one with enoxaparin
[60], and one with dalteparin [61], suggested a trend,
which was not statistically signiﬁcant, for better eﬃcacy
with split dosing. These authors estimated the incidence of
recurrent VTE at less than 5%. Should any patient develop
recurrent VTE during dose reduction of LMWH, it was
suggested to check the anti-Xa factor levels (as appropriate
to the type of LMWH used) after an injection and adjust
the dose accordingly [58, 61, 62]. The aforementioned
treatment algorithm (which had been extended to other
tumor types, e.g., breast cancer patients) was based on
experience. The use of a lower dose of LMWH after acute
treatment was felt consistent with the eﬃcacy of LMWH in
theprophylaxissetting(seealsoSection3)andhadevolvedas
a conceptual extrapolation. It has been the practice of many
neuro-oncologists to use LMWH indeﬁnitely in high grade
glioma patients. This is consistent with the experience in
a Eastern Cooperative Oncology Group (ECOG)/Radiation
Therapy Oncology Group (RTOG) trial, described in detail
in Section 3 below [63].
2.3. Other Adverse Side Eﬀects. It is worth noting that
patients receiving LMWH for extended periods are at
increased risk for osteoporosis, and may have other risk
factors for bone demineralization, such as the concurrent
use of steroids, hence, monitoring these patients with bone
mineral density studies, and considering interventions (e.g.,
bisphosphonates) as appropriate.
2.4. Alternatives to Low-Molecular-Weight Heparin and War-
farin in Treatment of VTE. Fondaparinux, a synthetic selec-
tive inhibitor of activated factor X (with no activity against
thrombin), is approved for the initial therapy of VTE [64].
In terms of cost and administration convenience, it is
comparable to LMWH. Fondaparinux, however, has not
beenstudiedspeciﬁcallyincancerpopulations.Asaresult,its
use in cancer patients has generally been limited in patients
who have a history of heparin-induced thrombocytopenia or
allergies to heparin [65].
The use of vena cava ﬁlters, as part of treatment of
VTE in cancer patients, is not well deﬁned, as previously
reviewed [65]. As is obvious, ﬁlters do not change the
underlying hypercoagulable state in cancer patients. The
use of ﬁlters in patients receiving anticoagulation has been
observed to reduce the incidence of symptomatic pulmonary
embolism, but also resulted in more recurrent DVTs and
no diﬀerence in overall survival [66]. Thus, many clinicians
believe ﬁlters should be reserved for situations in which
anticoagulant therapy is contraindicated, for example, severe
thrombocytopenia, active bleeding, or in anticipation of a
signiﬁcant neurosurgical intervention.
3.Low-Molecular-WeightHeparinas
Prophylaxis for Venous Thromboembolism
Cancer patients are at high risk of VTE, especially in
the setting of immobility, hospitalization, or surgery [13,
14, 16, 67]. However, randomized clinical trials of VTE
prophylaxis during hospitalization have been conducted in
general medical and surgical patients only. There has not
been a randomized trial in VTE prophylaxis targeting a
hospitalized medical (as opposed to surgical) cancer patient
population.Therehavebeenthreelarge,randomized,double
blind,placebo-controlledtrialsdemonstratingthebeneﬁtsof
anticoagulant prophylaxis, with LMWH or fondaparinux, in
general medical patients [68–70]. More than 1,000 hospital-
ized patients with either congestive heart failure, acute res-
piratory failure without requiring ventilator support, acute
infection, or acute rheumatic disorder in association with
an additional risk factor including cancer, were randomly
assigned to receive enoxaparin 40mg, enoxaparin 20mg,
or placebo subcutaneously once daily for 6 to 14 days; in
this study, 12.4% of patients had cancer [70]. The incidence
of VTE was signiﬁcantly lower in the group that received
enoxaparin 40mg (5.5%) than in the group that received
placebo (14.9%; RR = 0.37;P<. 001). There was no
signiﬁcant diﬀerence between the groups that received 20mg
of enoxaparin and placebo, respectively [70]. Similarly, the
incidence of VTE in patients hospitalized with an acute
medical condition was reduced from 4.96% in the group
that received placebo to 2.77% in the group that received
dalteparin 5,000 units subcutaneously once daily, represent-
ing a relative risk reduction of 45% (95% CI, 38% to 80%;
P = .0015) [69]. A subgroup analysis from the ﬁrst study
showed that cancer patients had an elevated risk of VTE and
that prophylaxis with 40mg of enoxaparin daily in cancer
patients led to a relative risk reduction of 0.5 (95% CI, 0.14
to 1.72), which was similar to the beneﬁts observed in the
whole group, despite being underpowered and not reaching
statistical signiﬁcance [71]. It can be inferred from these
studies that VTE prophylaxis with LMWH in hospitalized
cancer patients would be beneﬁcial.4 Thrombosis
For any given site of operation, patients with malignancy
undergoing surgery have a higher reported frequency of VTE
in the ﬁrst 90 days after operation [72]. In a multicenter,
randomized, and double-blind study, 332 patients undergo-
ing open curative surgery for abdominal or pelvic cancer
received one of two durations of postoperative prophylaxis
for VTE with enoxaparin 40mg once daily, either for 28
days postoperatively, or for 6 to 10 days after operation
until hospital discharge followed by placebo injections for a
further 21 days [73]. The frequency of VTE decreased from
12% in the placebo group to 4.8% in the treatment arm (P =
.02), based on screening venography at the end of the 28-
day period [73]. The beneﬁts of extended VTE prophylaxis
were maintained for 3 months after operation without any
evidence of a rebound thrombosis [73].
The role of VTE prevention in ambulatory patients with
cancer is controversial. In a randomized, placebo-controlled
European trial, 353 patients with metastatic breast cancer
received either certoparin at 3,000 anti-Factor Xa units daily
or placebo for 6 months; the rate of VTE in each treatment
group was 4% [74]. In a similarly designed trial, the rate
of VTE in 547 patients with stage III or stage IV nonsmall-
cell lung cancer was 4.5% in the LMWH arm compared
with 8.3% in patients receiving placebo (P = .07) [74]. In
a subgroup analysis involving patients with stage IV lung
cancer, LMWH led to a statistically signiﬁcant reduction
in VTE (10.1% versus 3.5%; P = .03). Certoparin is not
currently available in the United States.
The largest ambulatory study to date on VTE pro-
phylaxis was concluded by Agnelli and colleagues [52].
This study addressed the clinical beneﬁt of the LMWH,
that is, nadroparin, for the prophylaxis of thromboembolic
events in ambulatory patients receiving chemotherapy for
metastatic or locally advanced solid cancer. The primary
study endpoint was the incidence of symptomatic venous or
arterial thromboembolic events. Patients (n = 1150) were
randomized (2:1) between nadroparin and placebo group.
Results demonstrated 15 (2.0%) of 769 patients treated
with nadroparin and 15 (3.9%) of 381 patients treated with
placebo had a thromboembolic event (single-sided P = .02).
Five (0.7%) of 769 patients in the nadroparin group, and no
patients in the placebo group, had a major bleeding event
(two-sided P = .18). The incidences of minor bleeding were
7.4% (57 of 769) with nadroparin and 7.9% (30 of 381) with
placebo. There were 121 (15.7%) serious adverse events in
the nadroparin group and 67 (17.6%) serious adverse events
in the placebo group.
The CONKO 004 trial addressed chemotherapy with or
without LMWH, that is, enoxaparin (1mg/kg) in patients
(n = 312) with advanced pancreatic cancer [75]. The
primary endpoint was the reduction of symptomatic VTE
within the ﬁrst 12 weeks of treatment. Secondary endpoints
were toxicity, time to progression, and overall survival. There
were 22 VTE in 152 patients in the observation group
and 8 in 160 in the LMWH group. Per-protocol (PP) and
intent to treat (ITT) analyses demonstrated signiﬁcant risk
reductions from 14.5% to 5.0% (65% RRR) and 14.5%
to 3.8% (74% RRR) for LMWH, respectively. Similarly,
the UK FRAGEM study reported a 62% risk reduction in
VTE using the CLOT therapeutic regimen of dalteparin
(31% versus 12%; P = .02) [76]. Major bleeding events
were 9.9% for the observation group and 6.3% for LMWH
(ITT). In each group there was one tumor-related fatal
hemorrhage. Preliminary data demonstrated no diﬀerence
in time to progression, or survival for observation versus
LMWH, respectively, (19 versus 22 weeks) and (29 versus 31
weeks) [75].
3.1. Special Considerations for Low-Molecular-Weight
Heparin Prophylaxis
3.1.1. Neurosurgery. Prophylaxis in neurosurgical patients
has been studied as a unique patient cohort. Two multi-
center, randomized, double-blind trials studied the use of
LMWH (nadroparin 7500 units subcutaneously once daily,
or enoxaparin 40mg subcutaneously once daily, resp.) versus
placebo in conjunction with the use of compression stock-
ings in the prevention of VTE after elective neurosurgery
[77, 78]. The majority of the accrued patients had brain
tumors, up to 30% of whom were diagnosed with glioma
[78]. LMWH or placebo was given within 24 hours after
surgery and continued for up to 10 days or until hospital
discharge. Both studies showed that LMWH combined with
compression stockings was more eﬀective than compression
stockings alone for the prevention of VTE after elective
neurosurgery, without inducing any signiﬁcant increase of
major bleeding. In the nadroparin study [77] there was a
trend for a relative risk reduction in DVT of 28% with a
1.5% increase in nonfatal bleeding. The enoxaparin study
[78] demonstrated statistically signiﬁcant relative risk of 0.52
and no diﬀerence in major bleeding risk. However, it should
be noted that LMWH in these studies was given within 24
hours after surgery. Another randomized study conducted
at the University of Michigan, where LMWH (enoxaparin
30mg subcutaneously every 12 hours) was initiated before
the induction of anesthesia and was continued throughout
the hospital stay, showed that enoxaparin therapy initiated
at the time of anesthesia induction signiﬁcantly increased
postoperative intracranial hemorrhage [79]. This study was
terminated early because of the increased incidence of
adverse events in the enoxaparin treatment group. In conclu-
sion, LMWH given within 24 hours after neurosurgery, but
not prior to neurosurgery, in combination with compression
stockings, can be considered for the prevention of VTE in
glioma patients when continued for up to 10 days.
3.1.2. Glioma. As alluded to above, glioma patients are
highly predisposed to thromboembolic phenomena with
an incidence approaching ∼30% [55, 56]. In a phase II
study, Robins and colleagues studied patients with newly
diagnosed GBM: this patient group received dalteparin at
5,000 units daily during and after radiation [63]. The
primary endpoint of the study was survival; the secondary
end point was the incidence of VTE. This clinical trail
closed prematurely (n = 42), as standard of care for GBM
changed with the introduction of temozolomide [80]. As
the study was originally conceived it was estimated thatThrombosis 5
∼30% of the enrolled patients would develop VTE. Based
on statistical estimates, a study cohort of 72 patients was
planned,resultingin81%powerestimatetodetectadecrease
from 30% to 15% in VTE. When the study was concluded
there were no observed VTE in patients actively receiving
dalteparin. Time on dalteparin ranged from 1.2 months to
25.4 months, with a median time of 6.3 months. There were
noreportsofgrade3/4bleedingorthrombocytopeniarelated
to dalteparin before or aftert progression. There were local
site reactions to dalteparin (∼71% of patients); 2 patients
experienced grade 3 toxicities ascribed to radiation. Two
patients developed DVT after stopping dalteparin, at a time
when they had developed progressive GBM.
A seemingly contradictory result, reported by Perry and
colleagues, relates to a phase III Canadian study in which 186
malignant glioma patients were randomized to dalteparin
at 5,000 units daily versus placebo. Unfortunately, this trial
also closed prematurely, due to lack of drug availability. It
was planned to enroll 512 patients. In this study the primary
endpoint was the incidence of VTE. There was a trend for a
decrease in VTE; however, it was not statistically signiﬁcant
(HR = 0.51, 95% CI: 0.19–1.4, P = .29). There was also a
trend for increased bleeding in the LMWH arm, that is, 5.1%
(n = 5) versus 1.2% (n = 1) for the placebo. The clinical
signiﬁcance of this ﬁnding is uncertain, as intratumoral
hemorrhage is often part of the natural history of this disease
[57]. Noteworthy diﬀerences in these studies may relate to
diﬀerences in patient populations studied. The RTOG study
was restricted to GBM patients (as opposed to all malignant
glioma); there was also a requirement for an unusually good
performance status, that is, 95% ECOG performance status
o f0o r1[ 57].
The results of these two studies, taken collectively, leave
the role of thromboembolic prophylaxis with an anticoag-
ulant as undeﬁned for this group of patients with central
nervous system disease. As a result, further investigation
is required to reach deﬁnitive conclusions regarding the
application of VTE prophylaxis beyond the postoperative
period after hospital.
4. Coagulation as a Host Factor in Cancer
The association of disseminated intravascular coagulopathy
(DIC) and cancer is well documented in various malig-
nancies, including melanoma, breast, colon, gall bladder,
ovary, prostate, and stomach cancers [81]. This association
can be explained by general factors related to the host’s
response to cancer and, more speciﬁcally, to factors related
to procoagulant activities expressed by the cancer cells [82].
Thrombosis occurs in 5–15% of patients with cancer [83],
comparing to 0.1% in the general population [84].
Indeed, the occurrence of venous thrombosis in an
otherwise healthy person may be the ﬁrst sign of an occult
malignancy [85–87], as malignancy is often associated with
thromboembolic disease [81]. Investigations have shown
that ﬁbrin is abundant in the stroma of many tumors
[88–90]. The long-observed association of clotting with
malignancy prompted scientists over 30 years ago to test
the hypothesis that coagulation played an adjunctive role
in cancer progression. As reviewed by Zacharski and col-
leagues, a number of experimental animal studies (and
limited number of small-scale clinical trials in cancer
patients) suggested that anticoagulants, including heparin
and warfarin, might successfully inhibit tumor spread [91].
While a role for LMWHs (and perhaps heparin in general)
in cancer treatment can be logically argued based on
theories of ﬁbrin and tumor implantation, heparin may
have important antitumor eﬀects which are independent
of their anticoagulant properties. Folkman and colleagues,
for example, found that heparin fragments lacking evident
anticoagulant activity could still eﬀectively inhibit angiogen-
esis in presence of cortisone [92]. Other investigators have
reported that, individually, high-molecular-weight fractions
of heparin stimulate, while low-molecular-weight fractions
inhibit, angiogenesis and that this eﬀect was independent
of anticoagulation [93]. Furthermore, Bitan and colleagues
haveshownthattheabilityofheparinandheparinfragments
toinhibitmetastasisofmelanomas,byinhibitingheparinase-
dependent degradation of the extracellular matrix, was
the same in both anticoagulant and non-anticoagulant
fractions [94]. As cancers are most typically manifested by
uncontrolled cellular proliferation, it may also be relevant
that both anticoagulant and non-anticoagulant fractions of
heparin and heparin fragments can inhibit the proliferation
of vascular smooth muscle cells [95]. Collen and colleagues
have demonstrated the inhibitory eﬀect of heparins on
the proliferation of human microvascular endothelial cells,
which provides a novel mechanism by which LMWH may
aﬀect tumor progression, namely, reduced ingrowth of
microvascular structures in a ﬁbrinous stromal matrix by
rendering it less permissive for invasion [96].
5. AnticoagulationandCancer Survival
It is of historical interest to note that in 1976 the Veterans
Administration (VA) Cooperative Study Program initiated a
prospective randomized clinical trial of warfarin in cancer
patients to explicitly test the hypothesis that coagulation
was involved in cancer progression [91]. In providing a
rationale for their trial, the investigators proposed that
clotting may (1) facilitate attachment of metastatic tumor
cells to the endothelium; (2) provide growth factors for the
t u m o r ;( 3 )p r o v i d eas t r u c t u r a ll a t t i c ef o rc e l lp r o l i f e r a t i o n ;
(4) provide tumor cells protection from host immune
defenses [91]. As reported in 1984, the group found no
diﬀerences in survival between warfarin-treated and control
groups for several cancers. However, warfarin therapy was
associated with a signiﬁcant prolongation in the time to ﬁrst
evidence of disease progression (P = .016) and a signiﬁcant
improvement in survival (P = .018) for patients with small
cellcarcinomaofthelung,includingthesubgroupofpatients
with disseminated disease at the time of randomization (P =
.013) [97].
Interest in the potential relationship between neoplas-
tic diseases and coagulation followed the publication of
reports suggesting improved prognosis in cancer patients
with thrombosis receiving low-molecular weight-heparin
(LMWH) [98]. A meta-analysis of a number of randomized6 Thrombosis
clinical trials suggested the superiority of LMWH over
standard heparin in subgroups of patients with cancer [98].
Two early studies from this literature also suggest an unex-
pected and unexplained beneﬁt of LMWH as compared to
unfractionated heparin treatment: an apparent reduction in
cancer-related mortality in the ﬁrst three months following
initiationoftreatment[86,99].Areviewofpublishedclinical
trials involving LMWH as treatment and prophylaxis for
venous thrombosis analyzed a few other studies with data
on cancer-related mortality [100]. Although many LMWH
studieshavereportedpatients’baselinecharacteristics,which
sometimes included cancer, the follow-up periods were not
of signiﬁcant duration to allow a meaningful assessment of
treatment eﬀect on mortality. A meta-analysis of LMWH
versus unfractionated heparin (UFH) studies found the 90-
day mortality in patients with cancer in four studies to be
14% in the LMWH group, and 28% in the heparin group
(P = .01) [86, 99–102].
It is of interest to note that in the aforementioned CLOT
study (in Section 2 above), which was a randomized trial
of dalteparin for 6 months compared to dalteparin for a
brief initial period followed by a vitamin K antagonist,
survival was assessed as a secondary outcome; the primary
outcome was rate of recurrent thrombosis [53]. Survival was
not found to be improved in the dalteparin arm compared
with the control arm. However, a post hoc subgroup
analysis, focusing only on the patients with nonmetastatic
disease, reported the 12-month all-cause mortality of 35%
in vitamin K antagonist treated patients compared to 20%
in the dalteparin group (P = .04). Conversely, in patients
with metastatic cancer, no survival diﬀerence was observed
between dalteparin (72%) and oral anticoagulant (69%)
study arms (P = .46) [103].
LMWH has also been studied as an antineoplastic agent.
A randomized controlled study (n = 84) found a 4-
month improvement in progression free survival (P = .01)
in patients with small cell lung cancer patients receiving
combination chemotherapy with LMWH compared to those
who did not receive LMWH [104]. In another randomized,
placebo-controlled study (The Famous Trial) evaluated
385 patients with advanced malignancy receiving standard
treatment with or without dalteparin. Although there was
no statistically signiﬁcant beneﬁt overall in the dalteparin
arm, in a post hoc landmark analysis of 102 patients still
alive at 17 months, a signiﬁcant improvement in survival was
observed for patients receiving dalteparin [105]. A similar
observation was also made in a small study of GBM patients
reviewed in Section 3 [63], where better survival was seen in
patients maintained on dalteparin compared to those who
stopped dalteparin after ﬁrst disease progression. In another
randomized study (MALT) (n = 302) using nadroparin,
a signiﬁcant improvement in overall survival was observed
(relative risk, 0.75; 95% CI, 0.59 to 0.96; P = .02) [106].
However, a similar but smaller phase 3 study (n = 144) using
dalteparin was a negative trial [107].
The aforementioned laboratory and clinical studies
are a sampling of the mounting evidence that implicates
components of the clotting cascade and neoplastic tumor
progression. An excellent review of the subject has been
written by Kuderer and colleagues [34]. We agree with these
authors that LMWH and related agents hold promise for
improving cancer outcomes.
6. Conclusions
VTE is a signiﬁcant source of morbidity and mortality
for patients with cancer. LMWHs are safe and eﬀective
in treatment and prophylaxis of VTE. Continued research
regarding the antineoplastic activity of LMWH alluded to
abovemayprovidevaluableinsightsintocancerpathogenesis
and new treatment paradigms. Future controlled clinical
trials directed at evaluating antithrombotic agents relative to
treatment and prophylaxis are clearly warranted in this high-
risk population. Other areas for needed research include
markers and deﬁned patients pathways to better deﬁne
patient cohorts who are most likely to develop VTE.
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